(Eflornithine hydrochloride + sulindac) is under clinical development by Panbela Therapeutics and currently in Phase III for Colorectal Cancer. According to GlobalData, Phase III drugs for Colorectal Cancer have a 43% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Eflornithine hydrochloride + sulindac)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Eflornithine hydrochloride + sulindac) overview
Eflornithine hydrochloride in fixed-dose combination with sulindac (TP-09, CPP- 1X/sul) is under development for the treatment of attenuated familial adenomatous polyposis in pediatrics, colon adenomas, colorectal cancer and pancreatic cancer. The drug candidate is administered orally in the form of tablet. CPP-1X acts by targeting ornithine decarboxylase. Sulindac acts by targeting cyclic guanosine monophosphate-phosphodiesterase 5 (cGMP-PDE) which is involved in the control of apoptosis. Sulindac also controls tumor cell invasion by acting on NF-kappaB-mediated transcription of microRNAs. It affects translocation of NF-kappaB to the nucleus. It was under development for familial adenomatous polyposis in adults.
It was under development for the treatment of attenuated familial adenomatous polyposis, colon cancer and pancreatic cancer.
Panbela Therapeutics overview
Panbela Therapeutics (Panbela), formerly Sun BioPharma Inc is a biopharmaceutical company. It develops disruptive therapeutics for the treatment of pancreatic cancer and pancreatitis. The company’s pipeline products include SBP-101. Its SBP-101 produces superior anti-tumour activity in human cancer cell lines and is used for the treatment of patients with pancreatic ductal adenocarcinoma, and pancreatitis. The company offers clinical trials and drug development services. It partners with institutions, cancer centres universities, and research centres for the development of drugs. Panbela is headquartered in Waconia, Minnesota, the US.
For a complete picture of (Eflornithine hydrochloride + sulindac)’s drug-specific PTSR and LoA scores, buy the report here.